TNON news

Tenon Medical, Inc. filed a Form 4.1 to issue a Series B common stock purchase warrant to Armistice Capital Master Fund for up to 858,269 shares, reflecting a corporate financing event.

Tenon Medical successfully repaid $5.16 million of outstanding senior convertible promissory notes. The repayment removes a near-term debt obligation and mitigates potential future dilution for shareholders.

Tenon Medical Inc. regained compliance with Nasdaq's $1.00 minimum bid price requirement following its 1-for-35 reverse stock split, avoiding potential delisting. The recovery indicates improved stock liquidity and stability for the medical device manufacturer.

Tenon Medical announced it received notice from Nasdaq that it regained compliance with the minimum stockholders' equity requirement. The company regained compliance following the completion of a public offering completed in July 2026.

Tenon Medical has extended its consulting agreement with Richard Ferrari, who serves as Executive Chairman, for one additional year through May 6, 2027. Ferrari will continue to receive $180,000 annually in quarterly payments of $45,000.